Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Licenses Array Tech to Epigenomics for Oncology Tests

NEW YORK, June 27 (GenomeWeb News) - Affymetrix granted Epigenomics non-exclusive access to its microarray technology to develop microarray-based in vitro diagnostic tests for oncology, Epigenomics said today.


Epigenomics said the agreement complements its strategic alliance with Qiagen for sample preparation, announced last year.


Epigenomics will use the technologies to develop a platform for pathology tests based on its proprietary DNA methylation methods. Epigenomics will first develop pathology tests in prostate and breast cancer, the company said.


The company plans to transfer its molecular classification test for prostate cancer onto the Affymetrix platform to use it in clinical trials for FDA approval of the assay, scheduled to start next year.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.